Oscotec to Participate in BIO USA, Seeking Global Partnerships for Next-Generation PipelinesAug 24, 2026
Youngshin Kwak, Head of Oscotec Research Institute: “We Will Compete with Anti-Resistance Cancer Therapy Within 3 Years” [BioUSA]Aug 24, 2026
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor CevidoplenibJun 1, 2026
‘Oscotec proves competitiveness in targeting tau protein for Alzheimer’s treatment with tech transfer to Sanofi’Dec 26, 2025
[BIO USA] Oscotec advances ‘chemotherapy resistance novel drug’…“Expanding pipeline with at least two additional assets”Jun 26, 2025
Oscotec wins FDA nod for anti-resistance cancer trial, drops oral denfivontinib over safety issuesMay 2, 2025
